Advanced in Psoriasis

Bjorn Eliasson

Goeteborg, O, SE 
Advanced in Psoriasis
Goeteborg, O, SE 
OverviewLocationsClinical Research

Overview

Bjorn Eliasson practices in Goeteborg, Sweden. Dr. Eliasson is rated as an Advanced expert by MediFind in the treatment of Psoriasis. His top areas of expertise are Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), Maturity Onset Diabetes of the Young, Gastric Bypass, and Coronary Artery Bypass Graft (CABG).

His clinical research consists of co-authoring 243 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Psoriasis.

Gender
Male

Locations

Goeteborg, O, Sweden
Other Locations
Sweden
Uppsala, C, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
An Open, Single-arm, Multi Centre Pilot Investigation to Evaluate the Debriding Effect of ChloraSolv® on Chronic Wounds, Covered With Devitalised Tissue, During Six Weeks Treatment
An Open, Single-arm, Multi Centre Pilot Investigation to Evaluate the Debriding Effect of ChloraSolv® on Chronic Wounds, Covered With Devitalised Tissue, During Six Weeks Treatment
Enrollment Status: Completed
Publish Date: April 08, 2021
Intervention Type: Device
Study Phase: Not Applicable
View 1 Less Clinical Trial

243 Total Publications

SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications.
SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications.
Journal: Diabetes, obesity & metabolism
Published: October 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Eliasson's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 29 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile